London, United Kingdom, November 13, 2026
GSK plc has announced that its Bexsero (4CMenB) meningococcal group B vaccine has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for a single-dose booster in individuals aged 10 years and older who were previously vaccinated with Bexsero at least two years earlier. The recommendation represents an important development in meningococcal disease prevention, particularly for adolescents entering an age group associated with a second peak in invasive meningococcal disease incidence. The proposed label update is supported by clinical evidence demonstrating that immune memory established through vaccination during infancy can be effectively boosted with a single additional dose, even up to 19 years after the initial vaccination. If approved by the European Commission, the updated recommendation could provide greater flexibility for national immunisation programmes seeking to maintain protection against meningococcal B disease during adolescence.
Positive CHMP Opinion Supports a Single-Dose Booster Strategy
The positive CHMP opinion is based on evidence demonstrating that a single booster dose of Bexsero can strengthen immune responses in individuals who previously received primary vaccination during infancy. The recommendation specifically covers individuals aged 10 years and older who completed their earlier Bexsero vaccination series at least two years before receiving the booster. According to GSK, the clinical evidence indicates that immune memory established during infancy remains capable of responding effectively to a booster dose many years later. This finding is particularly relevant for public health vaccination strategies because protection against meningococcal disease needs to be considered throughout different stages of life. Adolescence represents an important period for maintaining immunity, as social interactions, close-contact environments and shared living arrangements can increase opportunities for bacterial transmission. The proposed single-dose approach could therefore help simplify booster vaccination strategies while supporting continued protection among previously vaccinated populations. However, the CHMP recommendation is not yet a final European Commission approval, and the updated indication remains subject to the applicable regulatory process.
Phase IIIb Men-B-096 Study Demonstrates Immune Response
The regulatory recommendation is supported by findings from Men-B-096, a Phase IIIb, open-label, multicentre clinical study evaluating the immune response and safety of a single Bexsero booster dose in healthy individuals aged 10 to 20 years. The study enrolled 312 participants across Finland, Italy, Spain and the United Kingdom. Among these participants, 234 had previously received Bexsero during infancy, while 78 had not previously received a meningococcal group B vaccine. The primary objective was to assess whether the immune response following a single booster dose in previously vaccinated participants was superior to the response following a first dose in adolescents without previous MenB vaccination. According to GSK, the study successfully met its primary endpoint, supporting the effectiveness of the booster strategy. The safety and reactogenicity profile observed following the single booster dose was consistent with the established safety profile of Bexsero in this age group. These findings provide additional clinical evidence supporting the ability of the vaccine to reactivate immune memory after an extended period following primary immunisation. The results strengthen the scientific basis for considering adolescent booster vaccination as part of long-term meningococcal disease prevention programmes.
Addressing the Risk of Invasive Meningococcal Disease
Invasive meningococcal disease (IMD) is a serious bacterial infection caused by Neisseria meningitidis, which can lead to meningitis and septicaemia. Although the disease is relatively uncommon, it can progress rapidly and may result in death or long-term complications despite medical treatment. Infants and young children experience the highest incidence of the disease, followed by a second increase among adolescents and young adults. In Europe, meningococcal serogroup B remains a leading cause of invasive meningococcal disease in individuals younger than 65 years. Adolescents may face increased exposure because of frequent social interactions, close-contact environments and shared personal spaces. Bexsero is currently registered in 61 countries for the prevention of invasive meningococcal disease caused by serogroup B. The vaccine is included in national or regional infant immunisation programmes in 15 European countries and adolescent immunisation programmes in three countries. GSK reports that approximately 140 million doses have been distributed globally since 2015. The proposed booster recommendation could help vaccination programmes extend protection into adolescence and strengthen public health efforts against meningococcal B infections. The latest regulatory development highlights GSK’s continued commitment to vaccine innovation, clinical research and infectious disease prevention. If the European Commission adopts the CHMP recommendation, the single-dose booster option could offer an additional approach for maintaining protection among adolescents previously vaccinated during infancy.
Source: GSK press release



